skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Datamonitor attended the Jefferies 2012 Global Healthcare Conference held in London over November 14–15, 2012.

 

This analysis review covers the key highlights of the conference:

Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS

 

The status of late-stage agents such as Roche’s Perjeta (pertuzumab) for breast cancer, Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec + insulin aspart) for type 2 diabetes, ImmunoGen’s trastuzumab emtansine (TDM1) for breast cancer, Rigel’s fostamatinib for rheumatoid arthritis, Aegerion’s lopidomide for homozygous familial hypercholesterolemia, NPS Pharmaceuticals’ Gattex (teduglutide) for short bowel syndrome and Natpara (recombinant human parathyroid hormone [1-84]) for the treatment of adult hypoparathyroidism, Cubist’s ceftolozane/tazobactam for complicated urinary tract infections and complicated intra-abdominal infections, and United Therapeutics’ implantable infusion.

 

Download our White Paper for the full analyst review.

Jefferies 2012 Global Healthcare Conference Review

 
This analysis review covers the key highlights of the conference:

Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS

 

Download our White Paper for the full analyst review.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: